ZINZINO AB (PUBL): PRELIMINARY SALES REPORT NOVEMBER 2019
Strong sales growth during November; Zinzino group revenue increased with a total of 30% compared with the previous year.
The revenue in November for Zinzino's sales markets increased by 38% to MSEK 69.1 (50.2) due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 42% and amounted to MSEK 3.2 (5.5) due to high level of internal production during the month. Overall the Group increased revenues by 30% to MSEK 72.3 (55.7) compared with the previous year.
Accumulated revenue for January – November 2019 increased by 30% MSEK 695.8 (534.8).
Revenues distributed as follows:
|Regions, MSEK||19-nov||18-nov||Change||YTD 2019||YTD 2018||Change|
|Europe Other Markets||28.8||11.4||153%||222.9||78.0||186%|
The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00,
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 10:30 the 11th of December 2019.
Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North.